Tuberc Respir Dis.  2008 Oct;65(4):285-291.

Polymorphisms in the SERPINA1 Gene and the Risk of Chronic Obstructive Pulmonary Disease in a Korean Population

• Cha SI
• Choi JE
• Lee JM
• Yoo SS
• Kim CH
• Lee WK
• Jung TH
• Kim NS
• Park JY

Abstract

BACKGROUND: We conducted a case-control study to evaluate the potential association between SERPINA1 genotypes (M1Val, M1Ala, S, and Z) and the risk COPD.
METHODS
The study population consisted of 93 patients with COPD and 112 healthy controls. The polymerase chain reaction and restriction fragment length polymorphism for detecting the SERPINA1 variants.
RESULTS
The M2 allele of the SERPINA1 gene was significantly associated with the risk of COPD in Koreans. The effect of the M2 allele on the risk of COPD was more pronounced in the subgroup <64 years.
CONCLUSION
These results suggest that SERPINA1 polymorphisms may contribute to a genetic predisposition for COPD. However, additional studies with larger sample sizes are required to confirm our findings.

Keyword

SERPINA1 gene; Polymorphism; COPD

MeSH Terms

Alleles
Case-Control Studies
Genetic Predisposition to Disease
Genotype
Humans
Polymerase Chain Reaction
Polymorphism, Restriction Fragment Length
Pulmonary Disease, Chronic Obstructive
Sample Size

Reference

1. Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. Clin Chest Med. 2000. 21:67–86.

2. Barnes PJ. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax. 1999. 54:245–252.

3. Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med. 1998. 157:1770–1778.

4. Sandford AJ, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Clin Chest Med. 2000. 21:633–643.

5. Hersh CP, Demeo DL, Silverman EK. Silverman EK, Shapiro SD, Lomas DA, Weiss ST, editors. Chapter 10. Chronic obstructive pulmonary disease. Respiratory genetics. 2005. 1st ed. London: Edward Arnold Publishers;253–296.

6. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983. 52:655–709.

7. Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988. 138:327–336.

8. Crystal RG. α1-antitrypsin deficiency, emphysema and liver disease: genetic basis and strategies for therapy. J Clin Invest. 1990. 85:1343–1352.

9. Fagerhol MK, Laurell CB. The Pi system-inherited variants of serum alpha 1-antitrypsin. Prog Med Genet. 1970. 7:96–111.

10. Mittman C, Barbela T, Lieberman J. Alpha 1-antitrypsin deficiency as an indicator of susceptibility to pulmonary disease. J Occup Med. 1973. 15:33–38.

11. α₁-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997. 75:397–415.

12. Crystal RG, Brantly ML, Hubbard RC, Curiel DT, States DJ, Holmes MD. The α₁-antitrypsin gene and its mutations: clinical consequences and strategies for therapy. Chest. 1989. 95:196–208.

13. Gaillard MC, Kilroe-Smith TA, Nogueira C, Dunn D, Jenkins T, Fine B, et al. Alpha-1-protease inhibitor in bronchial asthma: phenotypes and biochemical characteristics. Am Rev Respir Dis. 1992. 145:1311–1315.

14. Gaillard MC, Zwi S, Nogueira CM, Ludewick H, Feldman C, Frankel A, et al. Ethnic differences in the occurrence of the M1(ala213) haplotype of alpha-1-antitrypsin in asthmatic and non-asthmatic black and white South Africans. Clin Genet. 1994. 45:122–127.

15. Rieger S, Riemer H, Mannhalter C. Multiplex PCR assay for the detection of genetic variants of α₁-antitrypsin. Clin Chem. 1999. 45:688–690.

16. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001. 163:1256–1276.

17. Lucotte G, Sesboue R. Polymerase chain reaction detection of S and Z alpha-1-antitrypsin variants by duplex PCR assay. Mol Cell Probes. 1999. 13:389–391.

18. Park JY, Choi JE, Cha SI, Bae NC, Chae PH, Lee JY, et al. Prevalence of α₁-antitrypsin genotypes in Koreans. Tuber Respir Dis. 2001. 50:229–235.

19. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am. 1996. 80:501–522.

20. Silverman EK, Palmer LJ, Mosley JD, Barth M, Senter JM, Brown A, et al. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet. 2002. 70:1229–1239.

21. Vineis P. Molecular epidemiology: low-dose carcinogens and genetic susceptibility. Int J Cancer. 1997. 71:1–3.

22. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 1991. 51:5177–5180.

23. Xu LL, Wain JC, Miller DP, Thurston SW, Su L, Lynch TJ, et al. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev. 2001. 10:303–309.

24. Billingsley GD, Walter MA, Hammond GL, Cox DW. Physical mapping of four serpin genes: alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome 14q32.1. Am J Hum Genet. 1993. 52:343–353.

25. Rollini P, Fournier RE. A 370-kb cosmid contig of the serpin gene cluster on human chromosome 14q32.1: molecular linkage of the genes encoding alpha 1-antichymotrypsin, protein C inhibitor, kallistatin, alpha 1-antitrypsin, and corticosteroid-binding globulin. Genomics. 1997. 46:409–415.

26. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986. 89:370–373.